The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
More selling today by the looks of it. I just picked up some more shares at 10.60. At below 20x this years earnings, I think the stock represents excellent value at this level.
Someone sold £~950,000 worth of shares today. Should be a holding RNS shortly. I think after the interim statement and the positive outlook it is worth holding for the longterm. I will not be selling.
...should also have mentioned the dividend up 50% which is a genuine statement of intent from the BOD. A similar step for the fully year divvy will have the stock yielding around 4% which is rather unusual for a Company growing at this rate! just reminds us what a high ROCE/free cash flow business this is!
Figures look good, and stock looks like it's now on less than 20x this years earnings. One point for the market to ponder might be the license expiry in autumn 2017, which the commentary implies, might hold back growth in the year 2017/2018. My short term price target is still £15.
Go on my son...........
...that the directors are selling. Always a bit of a warning signal, and in this company, frankly a bit mystifying given the very positive statements from the management. Anyone else got thoughts on this?
Agree with 123 below, rating looks attractive even without potential Troponin revenues in 2017, so a free option on these 'dwarf[ing] the current business'. I do think £15 by year end is achievable.
Yes I was considering topping up also.
Bit of profit taking after a good run - nothing to worry about. I picked up a few more today below £11.
Sp down 4% today, can't see any reason.
I agree £15 is a reasonable target price. Strong balance sheet and current ratio should mean it survives any large market turbulence. The high sensitivity troponin test, should help drive future growth in 2017 onwards. Been some papers talking about it recently. To quote the last interm report "Revenues from this test (Troponin) could easily grow to dwarf the current business." http://www.bbc.co.uk/news/health-30896795 http://www.bmj.com/content/350/bmj.g7873.full.print?
Stock's now on 22 times earnings , but looks good for 30% growth for the next few years. I think we could see £15 before year end.
Someone seems to building a big stake in Bioventix at the moment.
Hi Matt, Have you seen the current ratio for this stock. It has a lovely balance sheet, dividend cover. What is not to like. For some reason LSE is not giving financial info for this. Go to morningstar they give you 5 years worth.
Hi Matt, No price target. I am in this for the long term. I like its financial characteristics, business structure/royalty payments. It is like abcam but more reasonably priced. How about you? Why are you here.
Yep, nice when a plan comes together - all too rare in these markets. Do you have a price target 123?
Profits are significantly ahead of market market expectations
It amazes me how it is possible to suppress the prices of these small companies. Still price is recovering. All the way to 920p at least.
http://maynardpaton.com/2015/05/06/bioventix-67-margins-from-monoclonal-antibodies/#more-1713
Considering how Abcam have risen and risen and risen (to the ridiculous valuation now). I think Bioventix could have a few positive years ahead. It is a conservatively run company, low CAPEX, lots of cash in the bank and 4 years of high ROCE >40% and high operating margins and a good dividend on top. Bioventix have specialized towards targeting small molecules rather than proteins like Abcam. They are also targeting there antibodies to the automated diagnostic market which takes a long time to validate with the individual machine and is therefore less likely to be replaced with cheaper antibody.
After listening to Paul Scott's Sunday night investor phone chats again from a few weeks ago and researched the company have decided to invest in this one.Hope to hold 2-3 years
http://www.stockopedia.com/content/small-cap-value-report-7-oct-2014-nxr-ultnfc-bvxp-snty-86829/